Hamish Innes, Sharon J. Hutchinson, Niels Obel, Peer B. Christensen, Esther J. Aspinall, David Goldberg, Henrik Krarup, Scott A. McDonald, Allan McLeod, Amanda Weir, Lars H. Omland – 16 January 2016 – Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the relative contribution of CHC per se versus adverse health behaviors is uncertain. We explored data on spontaneous resolvers of hepatitis C virus (HCV) as a benchmark group to uncover the independent contribution of CHC on liver mortality.

Tamar H. Taddei – 13 January 2016

Riccardo Lencioni, Thierry de Baere, Michael C. Soulen, William S. Rilling, Jean‐Francois H. Geschwind – 13 January 2016 – Transarterial chemoembolization (TACE) using lipiodol‐based regimens, including the administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta‐analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC.

Seema S. Desai, Jason C. Tung, Vivian X. Zhou, James P. Grenert, Yann Malato, Milad Rezvani, Regina Español‐Suñer, Holger Willenbring, Valerie M. Weaver, Tammy T. Chang – 11 January 2016 – Matrix rigidity has important effects on cell behavior and is increased during liver fibrosis; however, its effect on primary hepatocyte function is unknown. We hypothesized that increased matrix rigidity in fibrotic livers would activate mechanotransduction in hepatocytes and lead to inhibition of liver‐specific functions.

Marco Fiore, Lorenzo Andreana, Sebastiano Leone – 11 January 2016

Lei Zhao, Linda L. Wong, Xuetao Shi, Junfang Ji – 11 January 2016

George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen – 11 January 2016 – The possibility of safe discontinuation of therapy with nucleos(t)ide analogues (NAs) remains one of the most controversial topics in the management of chronic hepatitis B. Therefore, we systematically reviewed the existing data on NA discontinuation in this setting and tried to identify factors affecting the probability of posttherapy remission.

Anthony Cousien, Sylvie Deuffic‐Burban, Yazdan Yazdanpanah – 11 January 2016

Harel Dahari, Scot J. Cotler, Jordan J. Feld – 11 January 2016

Jean Michel Mansuy, Pierre Gallian, Chloé Dimeglio, Karine Saune, Catherine Arnaud, Bertrand Pelletier, Pascal Morel, Dominique Legrand, Pierre Tiberghien, Jacques Izopet – 11 January 2016 – Most cases of hepatitis E viral (HEV) infection in developed countries are autochthonous. Nevertheless, the reported seroprevalence of HEV varies greatly depending on the geographical area and the performance of the immunoassay used.